Hyperprogression — when cancer appears to accelerate on treatment

Hyperprogression is a pattern where a cancer's growth rate speeds up after starting immunotherapy, instead of slowing down as hoped. It is identified by comparing scans from before and after treatment began, not by a single scan's appearance. It is uncommon, and remains an area doctors and researchers are still studying closely.

This is different from ordinary disease progression, where a cancer keeps growing at roughly the pace it was growing before treatment, and different again from pseudoprogression, where a scan can briefly look worse as immune cells move into the tumour before it starts shrinking. Confirming which of these is happening needs at least two comparison points — your pre-treatment scan and at least one scan after starting immunotherapy — reviewed by your oncology team together with how you are feeling, not the report on its own.

Repeat imaging — including response-assessment PET-CT where your oncologist requests it — is coordinated for CION patients at accredited partner imaging centres; CION does not operate its own scanning equipment. This page explains the terminology in general terms and does not interpret any individual patient's scan.

These are patterns described across multiple published research studies, not a single official diagnostic checklist — no NCCN, ASCO or ESMO guideline has yet codified one definition, and different research groups use slightly different numeric cut-offs. Your oncologist interprets your specific scans against your specific history, not against a table.

Hyperprogression is uncommon. Published oncology studies estimate it affects roughly 5% to 20% of patients treated with immunotherapy, though the exact figure varies by cancer type, patient group, and which definition a study used — researchers have not settled on one confirmed rate.

Some studies have suggested it may be reported somewhat more often in older patients or in certain cancer types, but these associations are not consistent enough across research to be used as a prediction tool today. If you're currently being treated, this uncertainty is a reason your oncology team schedules early follow-up imaging — not a reason to expect it happens to most patients, because it does not.

Researchers don't yet have one confirmed explanation, and several biological mechanisms have been proposed rather than proven. Suggested mechanisms include: certain immune-checkpoint drugs unintentionally activating growth-related immune cells called regulatory T-cells; antibody-coated tumour cells being read by some immune cells as a growth signal rather than a target for destruction, an effect described in early laboratory research; and specific gene changes — such as MDM2/MDM4 amplification, seen in a minority of tumours — that some studies link to faster growth once immunotherapy starts.

None of these has been proven as the single cause, and different mechanisms may apply in different cancers. Being upfront about that — rather than offering a tidy explanation the evidence doesn't yet support — is deliberate on this page.

1. 1

   A focused repeat scan

   Usually sooner than your next routine scan, to confirm the growth pattern rather than react to one image.

2. 2

   Clinical correlation

   Your oncologist checks how you're actually feeling — pain, breathlessness, appetite, energy and any new symptoms — alongside the scan.

3. 3

   Tumour board review

   The finding is discussed by a multidisciplinary team, not decided by one report or one doctor alone.

4. 4

   A treatment-change conversation

   If confirmed, options such as switching therapy, treating a specific area directly, or a repeat biopsy to look for a targetable change are discussed with you and your family.

• One report, not a verdict — a single scan showing faster growth is a prompt for expert review, not a final answer on its own.
• Confirmed with more than one data point — your oncologist checks the pattern across scans and your clinical status before concluding anything.
• Other options usually remain — a change to one treatment does not mean every treatment option is exhausted; alternatives are typically discussed.
• Rare, not typical — most patients on immunotherapy do not experience this pattern; a worsening scan is far more often ordinary progression, which itself has other management options.

If you are looking at a scan report right now and it doesn't make sense, that feeling is common — bring it to a specialist rather than trying to interpret it alone.

• iRECIST: How Response Is Measured Differently for Immunotherapy — why immunotherapy scans are read against a different rulebook than chemotherapy scans.
• Partial Response and Complete Response: What the Words Mean — the vocabulary your report uses when treatment is working.
• A Confirmation Scan Was Ordered: What Does That Mean? — why doctors often wait for a second scan before changing a treatment plan either way.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through the immunotherapy journey.

This page explains hyperprogression terminology for general education only and does not interpret any individual patient's scan. Response-assessment imaging, including PET-CT, is coordinated at accredited partner imaging centres. Bring your report to a consultation for your oncologist's assessment of what it means for you.

Thousands of families have made sense of a confusing scan with us

A report that seems to say the opposite of what you were hoping for is frightening. Our oncologists take the time to explain what yours actually shows, in plain language.